HYPOLIPIDEMIC THERAPY IN THE COMPLEXITY OF IBS AND TYPE 2 DIABETES: MODERN OPPORTUNITIES AND PROSPECTS

Abstract

The combination of coronary heart disease (CHD) and type 2 diabetes mellitus (DM2) is associated with an extremely high cardiovascular risk and accelerated progression of atherosclerosis. Dislipidemia in type 2 diabetes has a specific aterogenic profile characterized by increased triglyceride levels, decreased cholesterol, high-density lipoproteins, and the presence of small dense particles of low-density lipoproteins. The article presents modern approaches to hypolipidemic therapy in this category of patients, including the use of statins, ezetimibe, PCSK9 inhibitors, and small interfering RNAs (inclysiran). Particular attention is paid to combined treatment strategies, their effectiveness and safety, as well as promising areas of therapy.